STOCK TITAN

[425] Semler Scientific, Inc. Business Combination Communication

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
425
Rhea-AI Filing Summary

Semler Scientific issued a Rule 425 communication related to the proposed acquisition of Semler Sci by Strive, Inc.. The notice references social media posts by Semler’s Director of Bitcoin Strategy and directs investors to Strive’s filed Form S-4, which registers Class A common stock to be issued in the transaction and will include a combined information statement, proxy statement, and prospectus. A definitive proxy/prospectus will be sent to Semler stockholders to seek approval. The communication identifies potential proxy participants, states it is not an offer or solicitation, and includes forward‑looking statement cautions with references to risk factor filings.

Semler Scientific ha emesso una comunicazione Rule 425 relativa all'acquisizione proposta di Semler Sci da parte di Strive, Inc.. L'avviso fa riferimento a post sui social media del Direttore della Strategia Bitcoin di Semler e indica agli investitori la informativa combinata presentata da Strive, che registra azioni ordinarie di Classe A da emettere nella transazione e includerà una informativa combinata, un proxy statement e un prospetto. Un proxy/prospetto definitivo sarà inviato agli azionisti di Semler per ottenere l'approvazione. La comunicazione identifica potenziali partecipanti al proxy, afferma che non si tratta di un'offerta o di una sollecitazione e include avvertenze su dichiarazioni future con riferimenti ai fascicoli di rischi.

Semler Scientific emitió una comunicación de la Regla 425 relacionada con la adquisición propuesta de Semler Sci por parte de Strive, Inc.. El aviso hace referencia a publicaciones en redes sociales del Director de Estrategia de Bitcoin de Semler y dirige a los inversionistas al Form S-4 presentado por Strive, que registra acciones comunes de Clase A a emitir en la operación y cubrirá una declaración informativa combinada, un proxy statement y un prospecto. Se enviará a los accionistas de Semler un proxy/prospecto definitivo para buscar su aprobación. La comunicación identifica posibles participantes en el proxy, señala que no es una oferta ni una solicitación y contiene advertencias sobre declaraciones futuras con referencias a los expedientes de factores de riesgo.

Semler ScientificStrive, Inc.에 의한 Semler Sci의 제안된 인수와 관련된 Rule 425 고지를 발행했습니다. 이 고지는 Semler의 비트코인 전략 이사의 소셜 미디어 게시물을 참조하고 투자자들에게 Strive의 제출된 Form S-4를 안내합니다. 해당 서류는 거래에서 발행될 Class A 보통주를 등록하며 결합된 정보성 진술, 위임장 진술서 및 전망서를 포함합니다. 확정적인 위임장/전망서는 Semler 주주들에게 발송되어 승인을 구하게 됩니다. 이 커뮤니케이션은 잠재적인 주주참여자들을 식별하고 이를 오퍼나 청약이 아니라고 명시하며, 위험 요인 파일링에 대한 참조가 있는 미래지향적 진술 주의사항을 포함합니다.

Semler Scientific a publié une communication Rule 425 relative à l'acquisition proposée de Semler Sci par Strive, Inc.. L'avis fait référence à des publications sur les réseaux sociaux du Directeur de la Stratégie Bitcoin de Semler et oriente les investisseurs vers le Form S-4 déposé par Strive, qui enregistre des actions ordinaires de Classe A à émettre dans la transaction et comprendra une déclaration d'informations combinée, une déclaration de procuration et un prospectus. Un prospectus/procuration définitif sera envoyé aux actionnaires de Semler pour obtenir l'approbation. La communication identifie les participants potentiels à la procuration, précise qu'il ne s'agit ni d'une offre ni d'une sollicitation et inclut des avertissements sur les déclarations prospectives avec des références aux dépôts de facteurs de risque.

Semler Scientific hat eine Rule-425-Mitteilung im Zusammenhang mit dem vorgeschlagenen Erwerb von Semler Sci durch Strive, Inc. veröffentlicht. Die Mitteilung verweist auf Social-Media-Beiträge von Semlers Direktor der Bitcoin-Strategie und verweist Investoren auf das von Strive eingereichte Form S-4, das im Rahmen der Transaktion auszugebene Class-A-Aktien registriert und eine zusammengefasste Informationsmitteilung, eine Vollmachtsmitteilung und einen Prospekt enthalten wird. Ein endgültiger Proxy/Prospekt wird den Semler-Aktionären zugesandt, um die Zustimmung zu erhalten. Die Mitteilung benennt potenzielle Proxy-Teilnehmer, gibt an, dass es kein Angebot oder keine Aufforderung ist, und enthält Hinweise zu zukunftsgerichteten Aussagen mit Verweisen auf Risikofaktorenakten.

Semler Scientific أصدر تواصلاً بموجب القاعدة 425 يتعلق بالاستحواذ المقترح على Semler Sci من قبل Strive, Inc. يشير الإشعار إلى منشورات على وسائل التواصل الاجتماعي لمدير استراتيجية البيتكوين في Semler ويوجه المستثمرين إلى Form S-4 الذي قدمته Strive ويُسجل أسهم عادية من الفئة A ستصدر في الصفقة وسيشمل بيان معلومات مركب، وبيان تفويض، ونشرة Prospective. سترسل توكيل/نشرة نهائية إلى مساهمي Semler seeking الموافقة. تحدد الرسالة المشاركين المحتملين في التوكيل، وتذكر أنها ليست عرضاً أو طلباً، وتحتوي على تحذيرات حول البيانات المستقبلية مع إشارات إلى ملفات عوامل الخطر.

Positive
  • None.
Negative
  • None.

Insights

Procedural merger communication; points to S-4 and proxy.

This notice is a permissible Rule 425 communication tied to Strive’s proposed acquisition of Semler Scientific. It references Strive’s Form S-4 registering Class A common stock to be issued in the transaction and the forthcoming combined information statement/proxy/prospectus for Semler’s shareholder vote.

The filing lists potential proxy solicitation participants and includes a standard no‑offer disclaimer. It also provides a forward‑looking statements caution and directs readers to SEC filings for detailed risk factors and terms. No financial terms or consideration details are provided in the excerpt.

The key next step is the delivery of the definitive information statement/proxy/prospectus to Semler stockholders for the approval process, as noted for October 28, 2025 communications context.

Semler Scientific ha emesso una comunicazione Rule 425 relativa all'acquisizione proposta di Semler Sci da parte di Strive, Inc.. L'avviso fa riferimento a post sui social media del Direttore della Strategia Bitcoin di Semler e indica agli investitori la informativa combinata presentata da Strive, che registra azioni ordinarie di Classe A da emettere nella transazione e includerà una informativa combinata, un proxy statement e un prospetto. Un proxy/prospetto definitivo sarà inviato agli azionisti di Semler per ottenere l'approvazione. La comunicazione identifica potenziali partecipanti al proxy, afferma che non si tratta di un'offerta o di una sollecitazione e include avvertenze su dichiarazioni future con riferimenti ai fascicoli di rischi.

Semler Scientific emitió una comunicación de la Regla 425 relacionada con la adquisición propuesta de Semler Sci por parte de Strive, Inc.. El aviso hace referencia a publicaciones en redes sociales del Director de Estrategia de Bitcoin de Semler y dirige a los inversionistas al Form S-4 presentado por Strive, que registra acciones comunes de Clase A a emitir en la operación y cubrirá una declaración informativa combinada, un proxy statement y un prospecto. Se enviará a los accionistas de Semler un proxy/prospecto definitivo para buscar su aprobación. La comunicación identifica posibles participantes en el proxy, señala que no es una oferta ni una solicitación y contiene advertencias sobre declaraciones futuras con referencias a los expedientes de factores de riesgo.

Semler ScientificStrive, Inc.에 의한 Semler Sci의 제안된 인수와 관련된 Rule 425 고지를 발행했습니다. 이 고지는 Semler의 비트코인 전략 이사의 소셜 미디어 게시물을 참조하고 투자자들에게 Strive의 제출된 Form S-4를 안내합니다. 해당 서류는 거래에서 발행될 Class A 보통주를 등록하며 결합된 정보성 진술, 위임장 진술서 및 전망서를 포함합니다. 확정적인 위임장/전망서는 Semler 주주들에게 발송되어 승인을 구하게 됩니다. 이 커뮤니케이션은 잠재적인 주주참여자들을 식별하고 이를 오퍼나 청약이 아니라고 명시하며, 위험 요인 파일링에 대한 참조가 있는 미래지향적 진술 주의사항을 포함합니다.

Semler Scientific a publié une communication Rule 425 relative à l'acquisition proposée de Semler Sci par Strive, Inc.. L'avis fait référence à des publications sur les réseaux sociaux du Directeur de la Stratégie Bitcoin de Semler et oriente les investisseurs vers le Form S-4 déposé par Strive, qui enregistre des actions ordinaires de Classe A à émettre dans la transaction et comprendra une déclaration d'informations combinée, une déclaration de procuration et un prospectus. Un prospectus/procuration définitif sera envoyé aux actionnaires de Semler pour obtenir l'approbation. La communication identifie les participants potentiels à la procuration, précise qu'il ne s'agit ni d'une offre ni d'une sollicitation et inclut des avertissements sur les déclarations prospectives avec des références aux dépôts de facteurs de risque.

Semler Scientific hat eine Rule-425-Mitteilung im Zusammenhang mit dem vorgeschlagenen Erwerb von Semler Sci durch Strive, Inc. veröffentlicht. Die Mitteilung verweist auf Social-Media-Beiträge von Semlers Direktor der Bitcoin-Strategie und verweist Investoren auf das von Strive eingereichte Form S-4, das im Rahmen der Transaktion auszugebene Class-A-Aktien registriert und eine zusammengefasste Informationsmitteilung, eine Vollmachtsmitteilung und einen Prospekt enthalten wird. Ein endgültiger Proxy/Prospekt wird den Semler-Aktionären zugesandt, um die Zustimmung zu erhalten. Die Mitteilung benennt potenzielle Proxy-Teilnehmer, gibt an, dass es kein Angebot oder keine Aufforderung ist, und enthält Hinweise zu zukunftsgerichteten Aussagen mit Verweisen auf Risikofaktorenakten.

Semler Scientific أصدر تواصلاً بموجب القاعدة 425 يتعلق بالاستحواذ المقترح على Semler Sci من قبل Strive, Inc. يشير الإشعار إلى منشورات على وسائل التواصل الاجتماعي لمدير استراتيجية البيتكوين في Semler ويوجه المستثمرين إلى Form S-4 الذي قدمته Strive ويُسجل أسهم عادية من الفئة A ستصدر في الصفقة وسيشمل بيان معلومات مركب، وبيان تفويض، ونشرة Prospective. سترسل توكيل/نشرة نهائية إلى مساهمي Semler seeking الموافقة. تحدد الرسالة المشاركين المحتملين في التوكيل، وتذكر أنها ليست عرضاً أو طلباً، وتحتوي على تحذيرات حول البيانات المستقبلية مع إشارات إلى ملفات عوامل الخطر.

Semler Scientific 发布了与 Strive, Inc. 收购 Semler Sci 的拟议相关的 Rule 425 通知。通知提到 Semler 的比特币策略主管在社交媒体上的帖子,并引导投资者查看 Strive 提交的 Form S-4,该表格登记在交易中将发行的 Class A 普通股,并将包括综合信息声明、代理声明和招股说明书。将向 Semler 的股东发送正式的代理/招股说明书以寻求批准。该通知确定了潜在的代理参与者,声明这不是要约或招揽,并包含对前瞻性声明的警告以及对风险因素备案的引用。

 

Filed by Semler Scientific, Inc.

(Commission File No.: 001-36305)

Pursuant to Rule 425 under the Securities Act of 1933, as amended

and deemed filed pursuant to Rule 14a-12

under the Securities Exchange Act of 1934

Subject Company: Semler Scientific, Inc.

(Commission File No.: 001-36305)

 

On October 28, 2025, Joe Burnett, Director of Bitcoin Strategy of Semler Sci, retweeted multiple posts to his X.com account concerning the proposed acquisition of Semler Sci by Strive, Inc. (“Strive”). The posts are provided below.

 

 

 

 

 

 

Additional Information and Where to Find It

 

In connection with the proposed transaction, Strive has filed with the SEC a Registration Statement on Form S-4, or the Registration Statement, to register the Class A common stock to be issued by Strive in connection with the proposed transaction and that will include an information statement of Strive, proxy statement of Semler Sci and a prospectus of Strive, or the Information Statement/Proxy Statement/Prospectus, and each of Strive and Semler Sci may file with the SEC other relevant documents concerning the proposed transaction.  A definitive Information Statement/Proxy Statement/Prospectus will be sent to the stockholders of Semler Sci to seek their approval of the proposed transaction.  BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF SEMLER SCI ARE URGED TO READ THE REGISTRATION STATEMENT AND INFORMATION STATEMENT/PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT STRIVE, SEMLER SCI AND THE PROPOSED TRANSACTION AND RELATED MATTERS.

 

A copy of the Registration Statement, Information Statement/Proxy Statement/Prospectus, as well as other filings containing information about Strive and Semler Sci, may be obtained, free of charge, at the SEC's website (http://www.sec.gov).  You will also be able to obtain these documents, when they are filed, free of charge, from Strive by accessing Strive's website at https://investors.strive.com/. Copies of the Registration Statement, the Information Statement/Proxy Statement/Prospectus and the filings with the SEC that will be incorporated by reference therein can also be obtained, without charge, by directing a request to Strive's Investor Relations department at 200 Crescent Court, Suite 1400, Dallas, Texas 75201 or by calling (855) 427-7360 or by submitting an inquiry at https://investors.strive.com/ir-resources/contact-ir. Copies of the documents filed with the SEC by Semler Sci will be available free of charge on Semler Sci’s website at https://ir.semlerscientific.com. The information on Strive’s or Semler Sci's respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

 

 

 

 

Participants in the Solicitation

 

Strive, Semler Sci and certain of their respective directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Semler Sci in connection with the proposed transaction.  Information about the interests of the directors and executive officers of Strive and Semler Sci and other persons who may be deemed to be participants in the solicitation of stockholders of Semler Sci in connection with the proposed transaction and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the Information Statement/Proxy Statement/Prospectus related to the proposed transaction, which will be filed with the SEC.  Information about the directors and executive officers of Semler Sci, their ownership of Semler Sci common stock, and Semler Sci's transactions with related persons is set forth in the section entitled "INFORMATION REGARDING OUR BOARD OF DIRECTORS AND CORPORATE GOVERNANCE," "EXECUTIVE OFFICERS," "SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT," “DIRECTOR COMPENSATION,” and "TRANSACTIONS WITH RELATED PERSONS" included in Semler Sci's definitive proxy statement in connection with its 2025 Annual Meeting of Stockholders, as filed with the SEC on July 17, 2025. Additional information regarding ownership of Semler Scientific’s securities by its directors and executive officers is included in such persons’ SEC filings on Forms 3 or 4, which are available at https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001554859. Information about the directors and executive officers of Strive is contained in Strive’s Current Report on Form 8-K filed with the SEC on September 15, 2025, Strive’s Current Report on Form 8-K filed with the SEC on October 6, 2025, Strive's Current Report on Form 8-K filed with the SEC on September 12, 2025 and under “Meet the Leadership Team” accessed through the “About Us” link on Strive’s website at https://strive.com/team. Additional information regarding ownership of Strive’s securities by its directors and executive officers is included in such persons’ SEC filings on Forms 3 or 4, which are available at https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=1920406. These documents and the other SEC filings described in this paragraph may be obtained free of charge as described above under the heading “Additional Information and Where to Find It.”

 

No Offer or Solicitation

 

This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or the solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or the Securities Act, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements.

 

Cautionary Statement Regarding Forward-Looking Statements

 

Certain statements herein and the documents incorporated herein by reference may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 3b-6 promulgated thereunder, which statements involve inherent risks and uncertainties.  Examples of forward-looking statements include, but are not limited to, statements regarding the outlook and expectations of Strive and Semler Sci, respectively, with respect to the proposed transaction, the strategic benefits and financial benefits of the proposed transaction, including the expected impact of the proposed transaction on the combined company's future financial performance, the timing of the closing of the proposed transaction, and the ability to successfully integrate the combined businesses.  Such statements are often characterized by the use of qualified words (and their derivatives) such as ”may,” “will,” ”anticipate,” “could,” “should,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “project,” “predict,” “potential,” “assume,” “forecast,” “target,” “budget,” “outlook,” “trend,” “guidance,” “objective,” “goal,” “strategy,” “opportunity,” and “intend,” as well as words of similar meaning or other statements concerning opinions or judgment of Strive, Semler Sci or their respective management about future events.  Forward-looking statements are based on assumptions as of the time they are made and are subject to risks, uncertainties and other factors that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results expressed or implied by such forward-looking statements.  Such risks, uncertainties and assumptions, include, among others, the following:

 

·the occurrence of any event, change or other circumstances that could give rise to the right of one or both of Strive and Semler Sci to terminate the merger agreement between Strive and Semler Sci;

 

 

 

 

·the possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not received or satisfied on a timely basis or at all;

 

·the outcome of any legal proceedings that may be instituted against Strive or Semler Sci or the combined company;

 

·the possibility that the anticipated benefits of the proposed transaction, including anticipated cost savings and strategic gains, are not realized when expected or at all, including as a result of changes in, or problems arising from, implementation of Bitcoin treasury strategies and risks associated with Bitcoin and other digital assets, general economic and market conditions, interest and exchange rates, monetary policy, laws and regulations and their enforcement;

 

·the possibility that the integration of the two companies may be more difficult, time-consuming or costly than expected;

 

·the possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events;

 

·the diversion of management's attention from ongoing business operations and opportunities;

 

·dilution caused by Strive's issuance of additional shares of its Class A common stock in connection with the proposed transaction;

 

·potential adverse reactions of Strive’s or Semler Sci’s customers or changes to business or employee relationships, including those resulting from the announcement or completion of the proposed transaction;

 

·changes in Strive’s or Semler Sci’s share price before closing; and

 

·other factors that may affect future results of Strive, Semler Sci or the combined company.

 

These factors are not necessarily all of the factors that could cause Strive’s, Semler Sci’s or the combined company's actual results, performance or achievements to differ materially from those expressed in or implied by any of the forward-looking statements.  Other factors, including unknown or unpredictable factors, also could harm Strive, Semler Sci's or the combined company's results.

 

Although each of Strive and Semler Sci believes that its expectations with respect to forward-looking statements are based upon reasonable assumptions within the bounds of its existing knowledge of its business and operations, there can be no assurance that actual results of Strive or Semler Sci will not differ materially from any projected future results expressed or implied by such forward-looking statements.  Additional factors that could cause results to differ materially from those described above can be found in Strive’s Annual Report on Form 10-K, Strive’s Form S-4 filed on August 6, 2025 and October 10, 2025, under the “Supplementary Risk Factors” filed as an exhibit to Strive’s Current Report on Form 8-K filed with the SEC on September 24, 2025, Semler Scientific’s most recent annual report on Form 10-K for the fiscal year ended December 31, 2024 and quarterly reports on Form 10-Q, and other documents subsequently filed by Strive and Semler Scientific with the SEC.

 

The actual results anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on Strive, Semler Sci or their respective businesses or operations.  Investors are cautioned not to rely too heavily on any such forward-looking statements.  Forward-looking statements speak only as of the date they are made and Strive and Semler Sci undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.

 

 

 

FAQ

What did SMLR disclose in this communication?

Semler Scientific issued a Rule 425 update regarding Strive’s proposed acquisition and referenced Strive’s filed Form S-4 and the forthcoming proxy/prospectus.

Will Semler Scientific (SMLR) stockholders vote on the transaction?

Yes. A definitive information statement/proxy statement/prospectus will be sent to Semler stockholders to seek their approval.

What is Strive’s Form S-4 registering?

It registers Strive’s Class A common stock to be issued in connection with the proposed acquisition.

Where can investors find the S-4 and related merger documents?

Documents are available free at www.sec.gov and via Strive’s and Semler Scientific’s investor relations websites.

Who may be participants in the proxy solicitation for SMLR?

Strive, Semler Scientific, and certain directors, executive officers, and employees may be deemed participants, as described in the proxy materials.

Is this communication an offer to sell securities or solicit votes?

No. It expressly states it is not an offer or solicitation; any offer would be made only by a prospectus meeting Securities Act requirements.

Does the notice include forward-looking statement cautions?

Yes. It warns of risks and uncertainties and refers to Strive’s S-4, 10-K, 8-K risk factors, and Semler’s 10-K/10-Q filings.
Semler Scientific Inc

NASDAQ:SMLR

SMLR Rankings

SMLR Latest News

SMLR Latest SEC Filings

SMLR Stock Data

393.55M
13.34M
11.96%
70.82%
16.91%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
CAMPBELL